Restart Life Sciences Corp. is a Canada-based life sciences company. The Company is focused on delivering wellness solutions that address health and lifestyle challenges. The Company is developing a portfolio of health-focused products, with a focus on brain health, cognitive function, and memory enhancement. The Company is focused on developing natural remedies specifically tailored for individuals on the autism spectrum. It offers BrainQ Cereal, which is crafted with a blend of whole grains, superfoods, and essential nutrients. It also offers Brain Balls, which is a functional snack designed to support cognitive performance, focus, and mental clarity. It owns Holy Crap Foods, which is a cereal brand made from organic seeds like chia, buckwheat, and hemp. Holy Crap is a gluten-free, plant-based, and non-genetically modified organism; its nutrient-dense blends support digestive health, balanced energy, and overall wellness.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

End-of-day quote Canadian Securities Exchange 23/01/2025			5-day change	1st Jan Change
0.0800 ^CAD	+14.29%		+60.00%	+33.33%

07-21	Restart Life Sciences Launches Updated AI-Driven E-Commerce Platform and Expands Holy Crap Foods Product Line	CI
07-15	Restart Life Sciences Corp. And University Of Manitoba Richardson Centre For Food Technology And Research Collaborate For Pre-Production Transition Of New Protein Frameworks	CI

Market Cap	4.36M 3.15M 2.72M 2.55M 2.32M 301M 4.44M 29.91M 11.7M 151M 11.81M 11.55M 501M	P/E 2024	6x	P/E 2025	-3.05x
Enterprise Value	2.96M 2.13M 1.84M 1.73M 1.57M 204M 3.01M 20.27M 7.92M 102M 8M 7.83M 339M	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	93.45%	Yield 2024 *	-	Yield 2025	-

07-21	Restart Life Sciences Launches Updated AI-Driven E-Commerce Platform and Expands Holy Crap Foods Product Line	CI
07-15	Restart Life Sciences Corp. And University Of Manitoba Richardson Centre For Food Technology And Research Collaborate For Pre-Production Transition Of New Protein Frameworks	CI
06-04	Restart Life Sciences Corp. Announces Chief Financial Officer Changes, Effective 04 June 2026	CI
06-03	Restart Life Sciences Appoints Inez Ho as Chief Financial Officer	MT
05-26	Restart Life Sciences Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-21	Restart Life Sciences Corp. announced that it has received CAD 0.1 million in funding	CI
05-16	Restart Life Sciences Corp. Advances New Product Relaunch Utilizing Acquired Intellectual Property Portfolio	CI
05-08	Restart Life Sciences Corp Appoints Lindsay Hamelin as Independent Director, Effective 08 May 2026	CI
05-08	Holy Crap Foods Inc. announced that it expects to receive CAD 0.1 million in funding from Restart Life Sciences Corp.	CI
05-08	Restart Life Sciences Corp. announced that it expects to receive CAD 0.1 million in funding	CI
04-30	Restart Life Sciences Corp and University of Manitoba Richardson Centre for Food Technology and Research Extend Research Collaboration	CI
04-25	Restart Life Sciences Corp. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-24	Restart Life Sciences Corp. Auditor Raises 'Going Concern' Doubt	CI

08-11	Restart Life Sciences Announces Production Launch of New Holy Crap Protein Line	NE
07-29	Restart Life Sciences Announces Strategic Focus on Targeted M&A Expansion in Health and CPG Sectors	NE
07-21	Restart Life Sciences Details U.S. E-Commerce Launch, AI Platform, and Three-Phase Expansion Strategy for Holy Crap Foods	NE
07-14	Restart Life Sciences Leverages University of Manitoba RCFTR Collaboration for Pre-Production Transition of New Protein Frameworks	NE
07-08	Restart Life Sciences Details Next-Generation Product Pipeline and Segment Expansion for Holy Crap	NE

Restart Life Sciences Corp. Stock Canadian Securities Exchange

Stocks

HEAL

CA76134J1075

Biotechnology & Medical Research

Valuation: Restart Life Sciences Corp.

Latest news : Restart Life Sciences Corp.

Press Releases: Restart Life Sciences Corp.

News in other languages: Restart Life Sciences Corp.

Quotes and Performance

Managers and Directors: Restart Life Sciences Corp.

Other Biotechnology & Medical Research

Financials

Company Profile

Income Statement and Estimates

16/06/22	Nova Mentis dépose un brevet portant sur le diagnostic, la surveillance et le traitement des maladies neurologiques à l'aide de dérivés psychoactifs de la tryptamine
09/06/22	Nova Mentis et la University of Central Florida vont développer un test permettant de mesurer la sérotonine dans la salive
07/06/22	Nova Mentis reçoit une autorisation d'exportation de substances contrôlées de la part du DEA américain pour son médicament exclusif à base de psilocybine le NM 1001
12/05/22	Nova Mentis accueille un analyste du comportement autistique dans son équipe scientifique
03/03/21	Nova Mentis Life Science: Nova Mentis beginnt mit Autismus-Mikrobiom-Studie in den Vereinigten Staaten

Manager	Title	Age	Since
Steve Loutskou CEO	Chief Executive Officer	-	22/10/2024
Inez Ho DFI	Director of Finance/CFO	42	03/06/2026
Kelly Pladson ADM	Chief Administrative Officer	44	01/02/2017

Director	Title	Age	Since
Georg Hochwimmer BRD	Director/Board Member	58	03/01/2024
Steve Loutskou CHM	Chairman	-	22/10/2024
Khavita Harrycharran BRD	Director/Board Member	-	10/12/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RESTART LIFE SCIENCES CORP.	+14.29%	+60.00%	-	-	3.15M
LONZA GROUP AG	+0.05%	-2.90%	+1.26%	+18.93%	48.42B
REVOLUTION MEDICINES, INC.	+0.85%	-0.70%	+460.88%	+581.30%	43.66B
BEONE MEDICINES AG	-2.40%	-0.23%	+8.13%	+80.67%	39.51B
IQVIA HOLDINGS INC.	-2.01%	-0.85%	+23.85%	+9.97%	38.95B
CELLTRION, INC.	-0.50%	+0.85%	+20.60%	+58.18%	32.61B
ASCENDIS PHARMA A/S	+0.38%	-3.23%	-	-	16.32B
MEDPACE HOLDINGS, INC.	-0.59%	-2.06%	+26.35%	+126.36%	16.15B
EUROFINS SCIENTIFIC SE	-1.42%	-0.86%	+3.12%	+26.72%	14.16B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.43%	+4.70%	+78.74%	+38.66%	13.37B
Average	+0.82%	-0.35%	+77.87%	+117.60%	29.24B
Weighted average by Cap.	-0.68%	-0.62%	+95.73%	+140.61%

	2024	2025
Net sales	-	-
Net income	225K 162K 140K 131K 120K 15.49M 228K 1.54M 602K 7.76M 608K 595K 25.77M	-1.39M -1M -865K -813K -740K -95.82M -1.41M -9.53M -3.73M -47.98M -3.76M -3.68M -159M
Net Debt	-86.02K -61.99K -53.54K -50.31K -45.75K -5.93M -87.44K -589K -230K -2.97M -233K -228K -9.86M	-1.41M -1.01M -876K -823K -748K -96.97M -1.43M -9.64M -3.77M -48.56M -3.81M -3.72M -161M